-
公开(公告)号：US20110150986A1
公开(公告)日：2011-06-23
申请号：US12731315
申请日：2010-03-25
Applicant: Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
Inventor： Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
IPC: A61K9/48 , A61K9/00 , A61K9/36 , A61K31/439
CPC classification number: A61K9/2072 , A61K9/2886 , A61K31/439 , A61K31/4709 , Y02A50/411
Abstract: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo.
Abstract translation: 本文公开了奎宁配方和使用奎宁制剂的方法。 本文具体公开的是固体口服剂型，其可以作为胶囊或片剂施用，或作为喷洒形式施用，患者经历很少或没有苦味。 剂型在体外和体内提供即时释放。
-
2.发明申请公开(公告)号：US20140057934A1
公开(公告)日：2014-02-27
申请号：US13971870
申请日：2013-08-21
Applicant: Siva Rama K. Nutalapati
Inventor： Siva Rama K. Nutalapati
IPC: A61K31/485 , A61M15/08 , A61M11/02
CPC classification number: A61K31/485 , A61M11/02 , A61M15/08
Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
Abstract translation: 公开了与口服剂型相比提供改善的生物利用度和可注射剂型提高患者依从性的甲基纳曲酮鼻制剂。 还公开了制备鼻制剂和使用方法，特别是治疗阿片类药物使用的副作用如便秘和其它适应症的方法。
-
公开(公告)号：US20110150992A1
公开(公告)日：2011-06-23
申请号：US12971051
申请日：2010-12-17
Applicant: Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
Inventor： Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
CPC classification number: A61K9/2072 , A61K9/2886 , A61K31/439 , A61K31/4709 , Y02A50/411
Abstract: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo.
Abstract translation: 本文公开了奎宁配方和使用奎宁制剂的方法。 本文具体公开的是固体口服剂型，其可以作为胶囊或片剂施用，或作为喷洒形式施用，患者经历很少或没有苦味。 剂型在体外和体内提供即时释放。
-
公开(公告)号：US20100159009A1
公开(公告)日：2010-06-24
申请号：US12641377
申请日：2009-12-18
Applicant: Zhongshui Yu , Kristin Arnold , Siva Rama K. Nutalapati
Inventor： Zhongshui Yu , Kristin Arnold , Siva Rama K. Nutalapati
CPC classification number: A61K31/40 , A61K9/2013 , A61K9/2027
Abstract: Disclosed herein are extended-release levetiracetam formulations having a matrix comprising levetiracetam and a hydrophobic excipient or an acrylic polymer excipient.
Abstract translation: 本文公开了具有包含左乙拉西坦和疏水赋形剂或丙烯酸聚合物赋形剂的基质的延长释放左乙拉西坦制剂。
-
公开(公告)号：US20130053399A1
公开(公告)日：2013-02-28
申请号：US13552684
申请日：2012-07-19
Applicant: Siva Rama K. Nutalapati
Inventor： Siva Rama K. Nutalapati
IPC: A61K31/495 , A61K31/4545 , A61P37/08 , A61K31/445
CPC classification number: A61K9/2054 , A61K9/0053 , A61K9/0056 , A61K9/0095 , A61K9/08 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2086 , A61K9/209 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/135 , A61K31/138 , A61K31/435 , A61K31/4402 , A61K31/4439 , A61K31/445 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/513 , A61K47/10 , A61K2300/00
Abstract: Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed.
Abstract translation: 公开了通过施用减毒剂量的第一代抗组胺剂快速起效并伴随维持剂量的第二代或第三代抗组胺药使用抗组胺药的组合的方法。
-
Patent Agency Ranking
公开(公告)号：US20120183605A1
公开(公告)日：2012-07-19
申请号：US13232581
申请日：2011-09-14
Applicant: Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
Inventor： Kristin Arnold , Matthew W. Davis , Suman Wason , Siva Rama K. Nutalapati
IPC: A61K9/48 , A61K31/439 , A61P33/00 , A61K9/00
CPC classification number: A61K9/2072 , A61K9/2846 , A61K31/439 , A61K31/4709 , A61K31/49 , Y02A50/411
Abstract: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo.
Abstract translation: 本文公开了奎宁配方和使用奎宁制剂的方法。 本文具体公开的是固体口服剂型，其可以作为胶囊或片剂施用，或作为喷洒形式施用，患者经历很少或没有苦味。 剂型在体外和体内提供即时释放。
-
公开(公告)号：US20090263478A1
公开(公告)日：2009-10-22
申请号：US12500199
申请日：2009-07-09
Applicant: Kristin Arnold , David F. Erkoboni , Rakeshkumar K. Lad , Siva Rama K. Nutalapati , Zhongshui Yu
Inventor： Kristin Arnold , David F. Erkoboni , Rakeshkumar K. Lad , Siva Rama K. Nutalapati , Zhongshui Yu
IPC: A61K9/58 , A61K31/403
CPC classification number: A61K9/1605 , A61K9/28 , A61K9/50
Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.
-
公开(公告)号：US09265757B2
公开(公告)日：2016-02-23
申请号：US13552684
申请日：2012-07-19
Applicant: Siva Rama K. Nutalapati
Inventor： Siva Rama K. Nutalapati
IPC: A61K31/445 , A61K31/435 , A61K31/513 , A61K31/4439 , A61K31/4402 , A61K31/496 , A61K31/138 , A61K31/4545 , A61K31/495 , A61K31/135 , A61K9/00 , A61K47/10 , A61K9/20
CPC classification number: A61K9/2054 , A61K9/0053 , A61K9/0056 , A61K9/0095 , A61K9/08 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2086 , A61K9/209 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/135 , A61K31/138 , A61K31/435 , A61K31/4402 , A61K31/4439 , A61K31/445 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/513 , A61K47/10 , A61K2300/00
Abstract: Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed.
Abstract translation: 公开了通过施用减毒剂量的第一代抗组胺剂快速起效并伴随维持剂量的第二代或第三代抗组胺药使用抗组胺药的组合的方法。
-
公开(公告)号：US20100183717A1
公开(公告)日：2010-07-22
申请号：US12687966
申请日：2010-01-15
Applicant: Kristin Arnold , Zhongshui Yu , Siva Rama K. Nutalapati
Inventor： Kristin Arnold , Zhongshui Yu , Siva Rama K. Nutalapati
CPC classification number: A61K9/2013 , A61K9/2866
Abstract: Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating.
Abstract translation: 本文公开了包含核心活性剂（例如阿夫唑嗪）和基本上用延长释放涂层涂覆的蜡赋形剂的芯的控释制剂。
-
公开(公告)号：US20100172979A1
公开(公告)日：2010-07-08
申请号：US12641488
申请日：2009-12-18
Applicant: Zhongshui Yu , Kristin Arnold , Siva Rama K. Nutalapati
Inventor： Zhongshui Yu , Kristin Arnold , Siva Rama K. Nutalapati
CPC classification number: A61K9/2866 , A61K31/40
Abstract: Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating.
Abstract translation: 本文公开了含有包含核心活性剂（例如左乙拉西坦）和蜡赋形剂的芯的控释制剂，其中芯基本上涂覆有延长释放的涂层。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.195 seconds)
